image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.2617
-6.4 %
$ 8.82 M
Market Cap
-0.22
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CODX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.262 USD, Co-Diagnostics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CODX stock under the base case scenario is HIDDEN Compared to the current market price of 0.262 USD, Co-Diagnostics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CODX stock under the best case scenario is HIDDEN Compared to the current market price of 0.262 USD, Co-Diagnostics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CODX

image
$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3$0.2$0.2Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
3.92 M REVENUE
-42.53%
-40.1 M OPERATING INCOME
6.15%
-37.6 M NET INCOME
-6.53%
-29.2 M OPERATING CASH FLOW
-32.03%
17.1 M INVESTING CASH FLOW
10.93%
104 K FINANCING CASH FLOW
107.62%
50.3 K REVENUE
-66.33%
-8.55 M OPERATING INCOME
28.18%
-7.53 M NET INCOME
31.71%
-8.75 M OPERATING CASH FLOW
-6.25%
7.36 M INVESTING CASH FLOW
2665.71%
355 K FINANCING CASH FLOW
241.38%
Balance Sheet Co-Diagnostics, Inc.
image
Current Assets 32.3 M
Cash & Short-Term Investments 29.7 M
Receivables 133 K
Other Current Assets 2.41 M
Non-Current Assets 31.7 M
Long-Term Investments 731 K
PP&E 4.88 M
Other Non-Current Assets 26.1 M
46.48 %3.77 %7.62 %40.78 %Total Assets$64.0m
Current Liabilities 7.32 M
Accounts Payable 3.29 M
Short-Term Debt 916 K
Other Current Liabilities 3.11 M
Non-Current Liabilities 1.24 M
Long-Term Debt 2.47 M
Other Non-Current Liabilities -1.24 M
38.52 %10.71 %36.32 %28.92 %Total Liabilities$8.6m
EFFICIENCY
Earnings Waterfall Co-Diagnostics, Inc.
image
Revenue 3.92 M
Cost Of Revenue 999 K
Gross Profit 2.92 M
Operating Expenses 43 M
Operating Income -40.1 M
Other Expenses -2.44 M
Net Income -37.6 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)4m(999k)3m(43m)(40m)2m(38m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.48% GROSS MARGIN
74.48%
-1023.75% OPERATING MARGIN
-1023.75%
-961.37% NET MARGIN
-961.37%
-69.30% ROE
-69.30%
-58.81% ROA
-58.81%
-69.69% ROIC
-69.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Co-Diagnostics, Inc.
image
50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -37.6 M
Depreciation & Amortization 1.38 M
Capital Expenditures -748 K
Stock-Based Compensation 5.43 M
Change in Working Capital 2.75 M
Others -938 K
Free Cash Flow -29.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Co-Diagnostics, Inc.
image
Wall Street analysts predict an average 1-year price target for CODX of $9 , with forecasts ranging from a low of $6 to a high of $12 .
CODX Lowest Price Target Wall Street Target
6 USD 2192.70%
CODX Average Price Target Wall Street Target
9 USD 3339.05%
CODX Highest Price Target Wall Street Target
12 USD 4485.40%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Co-Diagnostics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City. globenewswire.com - 1 month ago
Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Cath and I will be your conference operator today. seekingalpha.com - 1 month ago
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago. zacks.com - 1 month ago
Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. globenewswire.com - 1 month ago
Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. globenewswire.com - 1 month ago
All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2 months ago
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago. zacks.com - 2 months ago
Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will be in a listen-only mode. seekingalpha.com - 2 months ago
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results SALT LAKE CITY , March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. prnewswire.com - 2 months ago
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. prnewswire.com - 3 months ago
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit SALT LAKE CITY , March 6, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 4, 2025, the Securities & Governance Litigation Team at BakerHostetler, the legal firm retained to represent the Company, won complete dismissal on summary judgment of a Section 10(b) securities class action that had been pending against the Company in the United States District Court for the District of Utah. See Gelt Trading, Ltd. prnewswire.com - 3 months ago
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025 The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda, India SALT LAKE CITY , March 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company and CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will be hosting a symposium to honor International HPV (human papillomavirus) Awareness Day 2025. prnewswire.com - 3 months ago
8. Profile Summary

Co-Diagnostics, Inc. CODX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 8.82 M
Dividend Yield 0.00%
Description Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Contact 2401 South Foothill Drive, Salt Lake City, UT, 84109 https://www.codiagnostics.com
IPO Date July 12, 2017
Employees 132
Officers Mr. Richard David Abbott President Mr. Dan Bohrer CPA Vice President of Finance & Accounting Mr. Seth Egan Chief Commercialization Officer Mr. Christopher Thurston Chief Technology Officer Mr. Andrew Benson Head of Investor Relations Mr. Brian L. Brown CPA Chief Financial Officer & Company Secretary Mr. David Nielsen Chief Operating Officer Dr. Mayuranki Almaula Ph.D. Senior Vice President of Overseas Operations & Strategic Alliances Mr. Dwight H. Egan Chairman & Chief Executive Officer